Inspira Technologies’ ART100 Completes Clinical Evaluation and Enters Budgeted Procurement at Top U.S. Medical Center

Inspira Technologies Oxy BHN ( (IINN) ) has shared an announcement.

On January 29, 2026, Inspira Technologies announced that its FDA-cleared INSPIRA ART100 system has completed full clinical evaluation and progressed into a budgeted procurement execution process at a leading U.S. academic medical center ranked among the top hospitals nationwide. The ART100, which has successfully treated roughly 30 patients across life-saving procedures, surgeries and transplants at this institution, has moved from pilot use into the hospital’s standard clinical workflow with the clinical decision-making phase concluded, marking the first time the system has advanced from evaluation to a formal budgeted procurement pathway at a major U.S. academic center, a milestone the company views as validating the system’s real-world clinical performance and strengthening its U.S. commercial positioning.

The most recent analyst rating on (IINN) stock is a Sell with a $0.74 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.

Spark’s Take on IINN Stock

According to Spark, TipRanks’ AI Analyst, IINN is a Neutral.

The score is held down primarily by weak financial performance—minimal/erratic revenue, negative gross profit, ongoing net losses, and significant cash burn—implying continued dependence on external funding. Technical indicators are broadly neutral, offering limited offset, while valuation metrics provide little support due to a negative P/E and no dividend yield.

To see Spark’s full report on IINN stock, click here.

More about Inspira Technologies Oxy BHN

Inspira Technologies Oxy B.H.N. Ltd. is a commercial-stage medical device company focused on advanced respiratory support and real-time blood monitoring solutions. Its FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., forming the basis for the next-generation INSPIRA ART500 system aimed at providing oxygenation while patients remain awake and spontaneously breathing. The company is also developing HYLA, a proprietary blood sensor platform for continuous, non-invasive monitoring, and positions itself as an emerging life-support and MedTech platform with multiple cleared products and a growing IP portfolio.

Average Trading Volume: 170,784

Technical Sentiment Signal: Strong Sell

Current Market Cap: $28.23M

See more insights into IINN stock on TipRanks’ Stock Analysis page.